Developer docs
API playgroundTry for free, no card

Search company profiles

MorphoSys

Full company profile

uuid0003hg4

Namestring
MorphoSys
Legal namestring
MorphoSys AG
Websiteurl
morphosys.com
Company typeenum
Public
Founded yearint
1992
Descriptiontext

MorphoSys AG was a German biopharmaceutical company founded in 1992 and headquartered in Planegg, Germany, focused on the discovery and development of fully human antibody therapeutics for cancer. The company operated proprietary antibody discovery technology platforms and built a pipeline of investigational drugs targeting hematological malignancies and solid tumors, with a concentrated focus on hematology-oncology indications including myelofibrosis. Following the 2021 acquisition of Constellation Pharmaceuticals for $1.7 billion (financed in part through a Royalty Pharma partnership of up to $350 million), MorphoSys incorporated late-stage assets such as pelabresib into its pipeline, strengthening its position in rare blood cancers.

The company's revenue model centered on development and eventual commercialization of therapeutic antibodies through regulatory-approved pathways in Europe, Asia, and the United States, selling via traditional pharmaceutical distribution channels to hospitals, specialty oncology practices, and healthcare professionals serving hematology-oncology patients. It operated with 501–1,000 employees and raised capital through a mix of public equity and a December 2023 post-IPO capital increase of approximately €102.7 million at €30.00 per share.

In 2024, MorphoSys was acquired by Novartis AG for approximately €2.7 billion (~$2.9 billion), and the company was delisted from public markets and integrated into Novartis's hematology portfolio as a wholly owned subsidiary. The company therefore no longer operates as an independent commercial entity.

Short descriptiontext

MorphoSys AG was a German biopharmaceutical company founded in 1992 that discovered and developed fully human antibody therapeutics for hematology-oncology indications, serving cancer patients globally through healthcare providers. It was acquired by Novartis in 2024 for approximately €2.7 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersPlanegg, Germany
HQ citystring
Planegg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
antibody therapeutics, oncology drug development, hematology cancer treatments, biopharmaceutical research, immuno-oncology pipeline
Industry2 codes
1Cytokines, Interferons & Immunomodulatory Proteins
CodeHLAAAAACPrimaryYes
2Immunology & Inflammation Pharmaceuticals
CodeHLAIAAADPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Oncology Therapeutics
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MorphoSys AG discovers and develops fully human antibody therapeutics for the treatment of cancer, with a primary focus on hematology-oncology and rare hematologic malignancies. Its portfolio includes proprietary antibody drug candidates and late-stage assets such as pelabresib for myelofibrosis, acquired through the 2021 purchase of Constellation Pharmaceuticals for $1.7 billion. Following its 2024 acquisition by Novartis AG, MorphoSys's products are commercialized as part of Novartis's hematology portfolio across Europe, Asia, and the United States.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

MorphoSys AG is a German biotech company engaged in the discovery and development of novel antibodies for the treatment of cancer. The company has operated in the hematology-oncology space, developing therapeutic candidates for the treatment of hematological diseases and solid tumors. MorphoSys's portfolio included proprietary technology platforms for antibody discovery and a pipeline of investigational drugs. The company was acquired by Novartis in 2024 for approximately $2.9 billion, making it a wholly owned subsidiary and expanding Novartis's hematology portfolio.

Product and service1 record
1Pelabresib (BET inhibitor)
CategoryHematology-Oncology Therapeutics
Description

Pelabresib is a BET (bromodomain and extraterminal) inhibitor therapeutic candidate indicated for myelofibrosis and related hematologic malignancies. It is a late-stage oncology drug candidate acquired from Constellation Pharmaceuticals and intended for patients with rare blood cancers where treatment options are limited.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Tango Therapeutics
Strategic tierMinorTypeOthers
Description

Malte Peters, previously served as Chief Research and Development Officer at MorphoSys AG, joined Tango Therapeutics as President and CEO. This represents a personnel connection rather than a formal partnership.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers3 records
1MacroGenics
TypeDirect peer
2Genmab
TypeDirect peer
Description

Genmab is a Danish antibody therapeutics company specializing in fully human and humanized monoclonal antibodies for cancer. Direct peer to MorphoSys in antibody platform technology, hematology-oncology focus, and European biotech origin.

3Regeneron Pharmaceuticals
TypeBroad incumbent
Description

Regeneron is a large-cap biotech with a proprietary VelocImmune antibody platform and a diversified oncology/immunology pipeline including bispecifics competing in DLBCL. Broader incumbent with antibody discovery capabilities comparable to MorphoSys's HuCAL platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MorphoSys

Biopharmaceutical Oncology Therapeuticsmorphosys.com

MorphoSys AG was a German biopharmaceutical company founded in 1992 that discovered and developed fully human antibody therapeutics for hematology-oncology indications, serving cancer patients globally through healthcare providers. It was acquired by Novartis in 2024 for approximately €2.7 billion.

What MorphoSys does

MorphoSys AG was a German biopharmaceutical company founded in 1992 and headquartered in Planegg, Germany, focused on the discovery and development of fully human antibody therapeutics for cancer. The company operated proprietary antibody discovery technology platforms and built a pipeline of investigational drugs targeting hematological malignancies and solid tumors, with a concentrated focus on hematology-oncology indications including myelofibrosis. Following the 2021 acquisition of Constellation Pharmaceuticals for $1.7 billion (financed in part through a Royalty Pharma partnership of up to $350 million), MorphoSys incorporated late-stage assets such as pelabresib into its pipeline, strengthening its position in rare blood cancers.

The company's revenue model centered on development and eventual commercialization of therapeutic antibodies through regulatory-approved pathways in Europe, Asia, and the United States, selling via traditional pharmaceutical distribution channels to hospitals, specialty oncology practices, and healthcare professionals serving hematology-oncology patients. It operated with 501–1,000 employees and raised capital through a mix of public equity and a December 2023 post-IPO capital increase of approximately €102.7 million at €30.00 per share.

In 2024, MorphoSys was acquired by Novartis AG for approximately €2.7 billion (~$2.9 billion), and the company was delisted from public markets and integrated into Novartis's hematology portfolio as a wholly owned subsidiary. The company therefore no longer operates as an independent commercial entity.

MorphoSys firmographics

Firmographics
Name
MorphoSys
Legal name
MorphoSys AG
Website
https://morphosys.com
Company type
Public
Founded year
1992
Operating status
Acquired
Headcount range
501–1,000 employees
Short description
MorphoSys AG was a German biopharmaceutical company founded in 1992 that discovered and developed fully human antibody therapeutics for hematology-oncology indications, serving cancer patients globally through healthcare providers. It was acquired by Novartis in 2024 for approximately €2.7 billion.
Ownership category
akta.pro rank

MorphoSys industry classification

Industry
Product category
Biopharmaceutical Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
akta.pro secondary industry
Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

  • Antibody therapeutics
  • Oncology drug development
  • Hematology cancer treatments
  • Biopharmaceutical research
  • Immuno-oncology pipeline

Where MorphoSys is headquartered

Location

Headquarters

HQ city
Planegg
HQ country
Germany
HQ region
Europe

Markets served

MorphoSys business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

MorphoSys product offering

Product offering

Core offering

MorphoSys AG discovers and develops fully human antibody therapeutics for the treatment of cancer, with a primary focus on hematology-oncology and rare hematologic malignancies. Its portfolio includes proprietary antibody drug candidates and late-stage assets such as pelabresib for myelofibrosis, acquired through the 2021 purchase of Constellation Pharmaceuticals for $1.7 billion. Following its 2024 acquisition by Novartis AG, MorphoSys's products are commercialized as part of Novartis's hematology portfolio across Europe, Asia, and the United States.

Product overview

MorphoSys AG is a German biotech company engaged in the discovery and development of novel antibodies for the treatment of cancer. The company has operated in the hematology-oncology space, developing therapeutic candidates for the treatment of hematological diseases and solid tumors. MorphoSys's portfolio included proprietary technology platforms for antibody discovery and a pipeline of investigational drugs. The company was acquired by Novartis in 2024 for approximately $2.9 billion, making it a wholly owned subsidiary and expanding Novartis's hematology portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pelabresib (BET inhibitor) Pelabresib is a BET (bromodomain and extraterminal) inhibitor therapeutic candidate indicated for myelofibrosis and related hematologic malignancies. It is a late-stage oncology drug candidate acquired from Constellation Pharmaceuticals and intended for patients with rare blood cancers where treatment options are limited.

Companies that use MorphoSys

Customer profile

Segments2 records

Ideal customer profiles1 record

MorphoSys technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

MorphoSys partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Tango TherapeuticsminorOthersMalte Peters, previously served as Chief Research and Development Officer at MorphoSys AG, joined Tango Therapeutics as President and CEO. This represents a personnel connection rather than a formal partnership.

Scale indicators11 records

Recent moves8 records

Expansion highlights4 records

MorphoSys competitors and assessment

Company assessment

Direct peers

  • MacroGenics:
  • Genmab: Genmab is a Danish antibody therapeutics company specializing in fully human and humanized monoclonal antibodies for cancer. Direct peer to MorphoSys in antibody platform technology, hematology-oncology focus, and European biotech origin.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron is a large-cap biotech with a proprietary VelocImmune antibody platform and a diversified oncology/immunology pipeline including bispecifics competing in DLBCL. Broader incumbent with antibody discovery capabilities comparable to MorphoSys's HuCAL platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

MorphoSys social profiles

Digital presence

MorphoSys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MorphoSys leadership team

Management profile

Number of profiles

Profiles4 records

MorphoSys subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MorphoSys funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MorphoSys M&A and investment

M&A and investment

M&A3 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MorphoSys

What does MorphoSys do?

MorphoSys AG discovers and develops fully human antibody therapeutics for the treatment of cancer, with a primary focus on hematology-oncology and rare hematologic malignancies. Its portfolio includes proprietary antibody drug candidates and late-stage assets such as pelabresib for myelofibrosis, acquired through the 2021 purchase of Constellation Pharmaceuticals for $1.7 billion. Following its 2024 acquisition by Novartis AG, MorphoSys's products are commercialized as part of Novartis's hematology portfolio across Europe, Asia, and the United States.

Is MorphoSys a public or private company?

MorphoSys is a public company. It is classified as corporate owned and is currently acquired.

When was MorphoSys founded?

MorphoSys was founded in 1992. It employs 501 to 1,000 people.

Where is MorphoSys based?

MorphoSys is headquartered in Planegg, Germany, in the Europe region.

Who are MorphoSys's main competitors?

Direct peers on record are MacroGenics and Genmab. Regeneron Pharmaceuticals is listed as a broad incumbent.

Does MorphoSys have an API?

No public API is recorded for MorphoSys.

What industry is MorphoSys in?

MorphoSys's product category is Biopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerMajor Novartis shareholder calls for board shake-up after drug trial setbacksNovartis shareholder David Samra called for a board shake-up after the company's shares fell over 10% following a failed drug trial. He urged chairman Giovanni Caforio to improve oversight of acquisitions, citing a $12 billion Avidity deal that failed a late-stage study. Samra also criticized the compensation structure for relying on adjusted performance measures.The Straits TimesMajor Novartis shareholder calls for board shake-up after drug trial setbacksA major Novartis shareholder criticized the board's acquisition oversight after drug trial setbacks caused share losses, citing costly Avidity and MorphoSys deals. The shareholder praised CEO Vas Narasimhan but urged a review of board compensation to reflect economic realities.Gulf TimesMajor Novartis shareholder calls for board shakeup after drug trial setbacksDavid Samra of Artisan Partners called for a Novartis board shakeup after shares fell over 10% following failed drug trials. He urged chairman Giovanni Caforio to improve oversight of acquisitions, citing a $12bn Avidity deal that failed a late-stage study. Samra also urged compensation overhaul, while Novartis said guidance was unchanged.YahooINCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View RaisedIncyte Corporation reported second-quarter 2026 adjusted earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2.00, while total revenues of $1.67 billion grew 38% year over year, driven by strong Jakafi sales and a 173% surge in Opzelura cream sales to $449.7 million. The company raised its 2026 outlook following the quarter, with all major products either meeting or exceeding consensus estimates except for Iclusig and Niktimvo. Incyte gained exclusive global rights for tafasitamab from MorphoSys AG and, along with partner Syndax Pharmaceuticals, obtained FDA approval for the GVHD treatment axatilimab-csfr under the brand Niktimvo.GlobeNewswireIgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightThe IgA nephropathy market is projected to grow from $1.5 billion in 2025 to a higher value by 2036 at an 18.6% CAGR, driven by rising prevalence and novel therapies. The pipeline includes Phase III candidates like povetacicept and atacicept, with approvals such as VOYXACT already in place.Defense WorldMorphoSys (NASDAQ:MOR) & IMV (OTCMKTS:IMVIQ) Head to Head AnalysisThis article presents a side-by-side financial comparison of IMV Inc. and MorphoSys AG, analyzing metrics including gross revenue, earnings per share, valuation ratios, profitability, risk, and institutional ownership. The analysis finds that IMV beats MorphoSys on 6 of the 11 factors compared, while MorphoSys trades at a lower price-to-earnings ratio. IMV operates as a clinical-stage immuno-oncology company headquartered in Canada, while MorphoSys is a German biotech firm engaged in cancer therapeutics development across Europe, Asia, and the United States.GlobeNewswireProstate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of AdministrationResearchAndMarkets.com has published the 'Prostate Cancer - Competitive Landscape, 2026' report, covering 230+ companies and 265+ drugs in prostate cancer therapeutics, with key opportunities identified in androgen receptor degraders, radiopharmaceuticals, and immune-targeted therapies. The report highlights significant industry consolidation, including AstraZeneca's acquisition of Fusion Pharmaceuticals for targeted radiopharmaceuticals, AbbVie's purchase of ImmunoGen for ADC-based oncology assets, and Novartis's voluntary takeover offer for MorphoSys to expand its hematology portfolio. Strategic licensing collaborations such as Yuhan's exclusive license for Ubix Therapeutics' preclinical AR degrader program and BeiGene's partnership with Ensem Therapeutics for CDK2 inhibitor development further illustrate the shift toward personalized and precision medicine approaches in prostate cancer treatment.GlobeNewswireGlobal Orphan Drugs Market to Surpass USD 443 Billion by 2031 Driven by Advances in Genomics and Precision MedicineThe Global Orphan Drugs Market is projected to grow from USD 212.59 billion in 2025 to USD 443.07 billion by 2031, reflecting a CAGR of 13.02%, driven by regulatory incentives and advancements in genomics and precision medicine. Despite this growth, only 5% of approximately 7,000 known rare diseases had available treatments as of 2024, highlighting significant unmet medical need that continues to drive investment. Strategic M&A activity, exemplified by Novartis's €2.7 billion acquisition of MorphoSys, and AI-driven innovation are reshaping the sector as major pharmaceutical companies strengthen their rare disease portfolios.Bioanalysis-ZoneBiopharma’s new blueprint: why partnering and M&A are mission-criticalMajor pharmaceutical companies are shifting from mega-mergers to targeted, therapeutic-aligned M&A and partnerships as a strategic response to blockbuster patent expirations and pipeline pressures. J&J's US $14.6B acquisition of Intra-Cellular Therapies, Merck's US $10.8B purchase of Prometheus Biosciences, and Novartis' acquisitions of Anthos Therapeutics ($3.1B) and MorphoSys ($3B) exemplify this new acquisition playbook focused on late-stage, de-risked assets. The transformation reflects a broader industry consensus that quality and strategic fit now outweigh deal size, with companies prioritizing immunology, oncology, neuroscience and cardiometabolic niches.WikipediaWikipediaIncyte Corporation, an American pharmaceutical company, has executed several strategic acquisitions and partnerships to expand its therapeutic portfolio. Notable moves include the $1.4 billion acquisition of Villaris Therapeutics in 2022 and the $750 million purchase of Escient Pharmaceuticals in 2024, alongside significant licensing deals with Jiangsu Hengrui Medicine and MorphoSys.